80 results on '"Ribaudo, Heather J"'
Search Results
2. Pericoronary Adipose Tissue Density, Inflammation, and Subclinical Coronary Artery Disease Among People With HIV in the REPRIEVE Cohort.
- Author
-
Foldyna, Borek, Mayrhofer, Thomas, Zanni, Markella V, Lyass, Asya, Barve, Radhika, Karady, Julia, McCallum, Sara, Burdo, Tricia H, Fitch, Kathleen V, Paradis, Kayla, Fulda, Evelynne S, Diggs, Marissa R, Bloomfield, Gerald S, Malvestutto, Carlos D, Fichtenbaum, Carl J, Aberg, Judith A, Currier, Judith S, Ribaudo, Heather J, Hoffmann, Udo, and Lu, Michael T
- Subjects
CORONARY arterial radiography ,HIV infection complications ,HEART disease risk factors ,HIV-positive persons ,BIOMARKERS ,CONFIDENCE intervals ,INFLAMMATION ,PATHOLOGICAL anatomy ,CORONARY angiography ,RISK assessment ,COMPARATIVE studies ,CORONARY artery disease ,DESCRIPTIVE statistics ,RESEARCH funding ,LOGISTIC regression analysis ,COMPUTED tomography ,ODDS ratio ,LONGITUDINAL method ,DISEASE complications - Abstract
Background Pericoronary adipose tissue (PCAT) may influence plaque development through inflammatory mechanisms. We assessed PCAT density, as a measure of pericoronary inflammation, in relationship to coronary plaque among people with human immunodeficiency virus (HIV [PWH]) and to a matched control population. Methods In this baseline analysis of 727 participants of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) Mechanistic Substudy, we related computed tomography–derived PCAT density to presence and extent (Leaman score) of coronary artery disease (CAD), noncalcified plaque, coronary artery calcium (CAC), and vulnerable plaque features using multivariable logistic regression analyses. We further compared the PCAT density between PWH and age, sex, body mass index, CAC score, and statin use–matched controls from the community-based Framingham Heart Study (N = 464), adjusting for relevant clinical covariates. Results Among 727 REPRIEVE participants (age 50.8 ± 5.8 years; 83.6% [608/727] male), PCAT density was higher in those with (vs without) coronary plaque, noncalcified plaque, CAC >0, vulnerable plaque, and high CAD burden (Leaman score >5) (P <.001 for each comparison). PCAT density related to prevalent coronary plaque (adjusted odds ratio [per 10 HU]: 1.44; 95% confidence interval, 1.22–1.70; P <.001), adjusted for clinical cardiovascular risk factors, body mass index, and systemic immune/inflammatory biomarkers. Similarly, PCAT density related to CAC >0, noncalcified plaque, vulnerable plaque, and Leaman score >5 (all P ≤.002). PCAT density was greater among REPRIEVE participants versus Framingham Heart Study (−88.2 ± 0.5 HU versus −90.6 ± 0.4 HU; P <.001). Conclusions Among PWH in REPRIEVE, a large primary cardiovascular disease prevention cohort, increased PCAT density independently associated with prevalence and severity of coronary plaque, linking increased coronary inflammation to CAD in PWH. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Associations of Muscle Density and Area With Coronary Artery Plaque and Physical Function.
- Author
-
Erlandson, Kristine M., Umbleja, Triin, Lu, Michael T., Taron, Jana, Ribaudo, Heather J., Overton, Edgar T., Presti, Rachel M., Haas, David W., Sax, Paul E., Yin, Michael T., Zhai, Bingxue Kris, Louis, Rochelle, Upadhyay, Namrata, Eslami, Parastou, Douglas, Pamela S., Zanni, Markella V., Fitch, Kathleen V., Fulda, Evelynne S., Fichtenbaum, Carl J., and Malvestutto, Carlos D.
- Published
- 2023
- Full Text
- View/download PDF
4. Changes in Body Mass Index with Longer-term Integrase Inhibitor Use: A Longitudinal Analysis of Data from the Randomized Trial to Prevent Vascular Events in Human Immunodeficiency Virus (REPRIEVE).
- Author
-
Kileel, Emma M, Malvestutto, Carlos D, Lo, Janet, Fitch, Kathleen V, Fichtenbaum, Carl J, Aberg, Judith A, Zanni, Markella V, Martinez, Esteban, Okeke, Nwora Lance, Kumar, Princy, Joao, Esau, Bares, Sara H, Berrner, Daniel, Smieja, Marek, Roa, Jhoanna C, McCallum, Sara, Douglas, Pamela S, Ribaudo, Heather J, and Grinspoon, Steven K
- Subjects
HIV infections ,DISEASE clusters ,HIV integrase inhibitors ,CONFIDENCE intervals ,ANTIRETROVIRAL agents ,TREATMENT duration ,WEIGHT gain ,TREATMENT effectiveness ,RESEARCH funding ,DESCRIPTIVE statistics ,BODY mass index ,LONGITUDINAL method - Abstract
Over 2-years of follow-up, integrase strand transfer inhibitor (INSTI)-use was associated with weight gain among those on an INSTI <2 years at entry (+0.27 kg/m
2 /year; 95% confidence interval [CI],.22 to.33 vs +0.17 kg/m2 /year; 95% CI,.12 to.23; P =.01), but not those on an entry INSTI >2 years. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
5. Ideal cardiovascular health, biomarkers, and coronary artery disease in persons with HIV.
- Author
-
Douglas, Pamela S., McCallum, Sara, Lu, Michael T., Umbleja, Triin, Fitch, Kathleen V., Foldyna, Borek, Zanni, Markella V., Fulda, Evelynne S., Bloomfield, Gerald S., Fichtenbaum, Carl J., Overton, Edgar T., Aberg, Judith A., Malvestutto, Carlos D., Burdo, Tricia H., Arduino, Roberto C., Ho, Ken S., Yin, Michael T., Ribaudo, Heather J., and Grinspoon, Steven K.
- Published
- 2023
- Full Text
- View/download PDF
6. Coronary Artery Plaque Composition and Severity Relate to the Inflammasome in People With Treated Human Immunodeficiency Virus.
- Author
-
Schnittman, Samuel R, Kitch, Douglas W, Swartz, Talia H, Burdo, Tricia H, Fitch, Kathleen V, McCallum, Sara, Flynn, Jacqueline M, Fulda, Evelynne S, Diggs, Marissa R, Stapleton, Jack T, Casado, José L, Taron, Jana, Currier, Judith S, Zanni, Markella V, Malvestutto, Carlos, Fichtenbaum, Carl J, Aberg, Judith A, Ribaudo, Heather J, Lu, Michael T, and Douglas, Pamela S
- Abstract
Background Inflammasome activation is increased in people with human immunodeficiency virus (PWH), but its relationship with coronary plaque is poorly understood in this setting. Methods In a large human immunodeficiency virus cardiovascular prevention cohort, relationships between caspase-1, interleukin (IL)-1β, and IL-18 and coronary plaque indices were assessed by multivariate logistic regression. Results Higher IL-18 and IL-1β were associated with Leaman score, an integrative measure of plaque burden and composition. Conclusions As Leaman score >5 is associated with cardiovascular events in the general population, future work is needed to determine how the inflammasome relates to events and whether strategies to reduce its activation affect events or plaque progression among PWH. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Cytomegalovirus Immunoglobulin G (IgG) Titer and Coronary Artery Disease in People With Human Immunodeficiency Virus (HIV).
- Author
-
Schnittman, Samuel R, Lu, Michael T, Mayrhofer, Thomas, Burdo, Tricia H, Fitch, Kathleen V, McCallum, Sara, Fulda, Evelynne S, Zanni, Markella V, Foldyna, Borek, Malvestutto, Carlos, Fichtenbaum, Carl J, Aberg, Judith A, Bloomfield, Gerald S, Overton, Edgar T, Currier, Judith, Tebas, Pablo, Sha, Beverly E, Ribaudo, Heather J, Flynn, Jacqueline M, and Douglas, Pamela S
- Subjects
CYTOMEGALOVIRUSES ,HIV-positive persons ,CARDIOVASCULAR diseases risk factors ,BIOMARKERS ,INTERLEUKINS ,STATISTICS ,IMMUNOGLOBULINS ,BLOOD vessels ,CYTOMEGALOVIRUS diseases ,INFLAMMATION ,RISK assessment ,HIGHLY active antiretroviral therapy ,CORONARY artery disease ,RESEARCH funding ,COMPUTED tomography - Abstract
Background Cytomegalovirus (CMV) infection is thought to result in increased immune activation in people with human immunodeficiency virus (HIV, PWH). Although some data have linked asymptomatic CMV infection to cardiovascular disease among PWH, it remains unknown whether CMV is associated with increased or high-risk coronary plaque. Methods The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) enrolled PWH aged 40–75 years on stable antiretroviral therapy (ART) with low-to-moderate atherosclerotic cardiovascular disease (ASCVD) risk. Among a subset of US REPRIEVE participants, coronary plaque was assessed by coronary computed tomography angiography. Here, we assessed the relationship between CMV immunoglobulin G (IgG) titer and (1) levels of immune activation, (2) inflammatory biomarkers, and (3) coronary plaque phenotypes at study entry. Results Of 672 participants, mean age was 51 years, 83% were men, median ASCVD risk score was 4.5%, and 66% had current CD4+ T-cell count ≥500 cells/mm
3 . Higher CMV IgG quartile group was associated with older age and lower current and nadir CD4+ T-cell counts. CMV IgG titer was associated with specific inflammatory biomarkers (sCD163, MCP-1, interleukin [IL]-6, hsCRP) in univariate analysis, but not after controlling for HIV-specific factors. In contrast, CMV IgG titer was not associated with coronary artery disease indexes, including presence of plaque, coronary artery calcium (CAC) score >0, vulnerable plaque presence, or Leaman score >5. Conclusions No meaningful association was seen between CMV IgG titer and coronary artery disease indexes among ART-treated PWH at study enrollment. Longitudinal assessments in REPRIEVE will determine the relationship of CMV IgG titer to plaque progression and cardiovascular events. Clinical Trials Registration NCT02344290. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
8. Diet in a global cohort of adults with HIV at low-to-moderate traditional cardiovascular disease risk.
- Author
-
Fitch, Kathleen V., McCallum, Sara A., Erlandson, Kristine M., Overton, Edgar Turner, Zanni, Markella V., Fichtenbaum, Carl, Aberg, Judith A., Fulda, Evelynne S., Kileel, Emma M., Moran, Laura E., Bloomfield, Gerald S., Novak, Richard M., Pérez-Frontera, Sigrid, Abrams-Downey, Alexandra, Pierone Jr., Gerald, Kumarasamy, Nagalingeswaran, Ruxrungtham, Kiat, Mngqibisa, Rosie, Douglas, Pamela S., and Ribaudo, Heather J.
- Published
- 2022
- Full Text
- View/download PDF
9. Geographical Differences in the Self-Reported Functional Impairment of People With Human Immunodeficiency Virus (HIV) and Associations With Cardiometabolic Risk.
- Author
-
Erlandson, Kristine M, Fitch, Kathleen V, McCallum, Sara A, Ribaudo, Heather J, Overton, Edgar T, Zanni, Markella V, Bloomfield, Gerald S, Brown, Todd T, Fichtenbaum, Carl J, Bares, Sara, Aberg, Judith A, Douglas, Pamela S, Fulda, Evelynne S, Santana-Bagur, Jorge L, Castro, Jose G, Moran, Laura E, Mave, Vidya, Supparatpinyo, Khuanchai, Ponatshego, Ponego L, and Schechter, Mauro
- Subjects
HIV infection complications ,HIV-positive persons ,CARDIOVASCULAR diseases risk factors ,RESEARCH ,HIV infections ,CONFIDENCE intervals ,SELF-evaluation ,FUNCTIONAL status ,POPULATION geography ,RANDOMIZED controlled trials ,HIGHLY active antiretroviral therapy ,BLIND experiment ,DESCRIPTIVE statistics ,DATA analysis software ,LONGITUDINAL method - Abstract
Background We sought to explore multinational differences in functional status by global burden of disease (GBD) regions in the REPRIEVE cohort. Methods REPRIEVE is a prospective, double-blind, randomized, placebo-controlled, multicenter, phase III primary cardiovascular prevention study of pitavastatin calcium vs placebo among people with human immunodeficiency virus (HIV, PWH) ages 40–75 on antiretroviral therapy (ART). GBD super regions were defined using World Health Organization classifications. Participants were categorized by impairment on the Duke Activity Status Instrument (DASI: none, some, moderate, severe). Logistic regression models examined risk factors and GBD regions associated with functional impairment. The association between functional impairment and cardiometabolic risk was also explored. Results Of 7736 participants, the majority were from high-income countries (n = 4065), were male (65%), and had received ART for ≥ 10 years. The median DASI score was 58.2 (interquartile range [IQR] 50.2, 58.2); 36% reported at least some impairment. In adjusted analyses, functional impairment was significantly more frequent among participants from Southeast/East Asia. Other factors associated with greater impairment included female sex, Black race, older age, current/former smoking, higher body mass index, use of ART for ≥ 10 years, and select ART regimens; differences were seen in risks across GBD regions. Functional impairment was associated with increased cardiometabolic risk. Conclusions Over 1/3 of middle-aged and older PWH in a global cohort across diverse GBD regions demonstrate functional impairments. The associations between DASI and cardiometabolic risk suggest that a measure of functional status may improve risk prediction; these longitudinal associations will be further investigated over REPRIEVE trial follow-up. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
10. Methotrexate Inhibits T Cell Proliferation but Not Inflammatory Cytokine Expression to Modulate Immunity in People Living With HIV.
- Author
-
Freeman, Michael L., Clagett, Brian M., Moisi, Daniela, Yeh, Eunice, Morris, Charles D., Ryu, Angela, Rodriguez, Benigno, Stein, James H., Deeks, Steven G., Currier, Judith S., Hsue, Priscilla Y., Anthony, Donald D., Calabrese, Leonard H., Ribaudo, Heather J., and Lederman, Michael M.
- Subjects
INHIBITION of cellular proliferation ,HIV-positive persons ,FOLIC acid ,TETRAHYDROFOLATE dehydrogenase ,T cells ,METHOTREXATE ,REDUCTASE inhibitors ,IMMUNE reconstitution inflammatory syndrome - Abstract
Inflammation associated with increased risk of comorbidities persists in people living with HIV (PWH) on combination antiretroviral therapy (ART). A recent placebo-controlled trial of low-dose methotrexate (MTX) in PWH found that numbers of total CD4 and CD8 T cells decreased in the low-dose MTX arm. In this report we analyzed T cell phenotypes and additional plasma inflammatory indices in samples from the trial. We found that cycling (Ki67+) T cells lacking Bcl-2 were reduced by MTX but plasma inflammatory cytokines were largely unaffected. In a series of in vitro experiments to further investigate the mechanisms of MTX activity, we found that MTX did not inhibit effector cytokine production but inhibited T cell proliferation downstream of mTOR activation, mitochondrial function, and cell cycle entry. This inhibitory effect was reversible with folinic acid, suggesting low-dose MTX exerts anti-inflammatory effects in vivo in PWH largely by blocking T cell proliferation via dihydrofolate reductase inhibition, yet daily administration of folic acid did not rescue this effect in trial participants. Our findings identify the main mechanism of action of this widely used anti-inflammatory medicine in PWH and may provide insight into how MTX works in the setting of other inflammatory conditions. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
11. Prevalence and Correlates of Electrocardiographic Abnormalities in Adults With HIV: Insights From the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE).
- Author
-
Bloomfield, Gerald S., Weir, Isabelle R., Ribaudo, Heather J., Fitch, Kathleen V., Fichtenbaum, Carl J., Moran, Laura E., Bedimo, Roger, de Filippi, Christopher, Morse, Caryn G., Piccini, Jonathan MHS, Zanni, Markella V., Lu, Michael T., Hoffmann, Udo, Grinspoon, Steven K., and Douglas, Pamela S.
- Published
- 2022
- Full Text
- View/download PDF
12. COVID-19 Vaccination Rates in a Global HIV Cohort.
- Author
-
Fulda, Evelynne S, Fitch, Kathleen V, Overton, Edgar T, Zanni, Markella V, Aberg, Judith A, Currier, Judith S, Lu, Michael T, Malvestutto, Carlos, Fichtenbaum, Carl J, Martinez, Esteban, Umbleja, Triin, Douglas, Pamela S, Ribaudo, Heather J, and Grinspoon, Steven K
- Subjects
COVID-19 vaccines ,COVID-19 ,CLINICAL trial registries ,CORONAVIRUS diseases ,GLOBAL burden of disease ,COVID-19 pandemic - Abstract
Little is known regarding coronavirus disease 2019 (COVID-19) vaccination rates in people with HIV (PWH), a vulnerable population with significant morbidity from COVID-19. We assessed COVID-19 vaccination rates among 6952 PWH in the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) compared to region- and country-specific vaccination data. The global probability of COVID-19 vaccination through end of July 2021 was 55% among REPRIEVE participants with rates varying substantially by Global Burden of Disease (GBD) superregion. Among PWH, factors associated with COVID-19 vaccination included residence in high-income regions, age, white race, male sex, body mass index, and higher cardiovascular risk. Clinical Trials Registration. NCT02344290. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
13. Assessment of Obesity and Cardiometabolic Status by Integrase Inhibitor Use in REPRIEVE: A Propensity-Weighted Analysis of a Multinational Primary Cardiovascular Prevention Cohort of People With Human Immunodeficiency Virus.
- Author
-
Kileel, Emma M, Lo, Janet, Malvestutto, Carlos, Fitch, Kathleen V, Zanni, Markella V, Fichtenbaum, Carl J, Overton, Edgar T, Okeke, Nwora Lance, Kumar, Princy, Joao, Esau, Aberg, Judith A, Martinez, Esteban, Currier, Judith S, Douglas, Pamela S, Ribaudo, Heather J, and Grinspoon, Steven K
- Abstract
Background Emerging data demonstrate that the use of integrase inhibitor (INSTI)-based antiretroviral treatment (ART) is associated with increased weight, but the cardiometabolic health consequences of increased weight remains poorly understood. Methods This analysis examined INSTI use (>6 months) at entry among REPRIEVE participants enrolled in High Income and Latin America/Caribbean Global Burden of Disease regions. Primary analyses used linear and logistic regression; secondary analyses used quantile regression to examine differences across the full data distribution. Characteristics of those with and without INSTI use were balanced using inverse probability of treatment weighting. Results Among 4500 REPRIEVE participants, 1848 were on an INSTI-based regimen at entry for an average of 2.1 ± 1.8 years. Integrase inhibitor use (vs no INSTI use) was associated with higher odds of obesity (odds ratio [OR], 1.63; 95% confidence interval [CI], 1.4–1.9) and higher mean body mass index ([BMI] +1.5kg/m2; 95% CI, 1.0–1.9) and waist circumference (+3.6cm; 95% CI, 2.6–4.6). Differences in weight related to INSTI use were greater in the upper tails of the distribution (+3.1kg/m2 [95% CI, 1.9–4.4] at the 90th centile vs +0.7kg/m2 [95% CI, 0.2–1.2] at the 50th centile) and among women and nonwhite participants, with sex and race having an additive effect on BMI. Conversely, INSTI use was not associated with differences in glucose, low-density lipoprotein cholesterol, or higher odds of metabolic syndrome or hypertension. Conclusions Differences in weight and waist circumference associated with INSTI use are (1) not uniform across people with human immunodeficiency virus, (2) greatest among women and nonwhites, and (3) concentrated at the upper tails of weight distribution. These data identify at-risk subgroups for whom long-term cardiovascular disease outcomes should be carefully assessed. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
14. Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial.
- Author
-
Douglas, Pamela S, Umbleja, Triin, Bloomfield, Gerald S, Fichtenbaum, Carl J, Zanni, Markella V, Overton, Edgar T, Fitch, Kathleen V, Kileel, Emma M, Aberg, Judith A, Currier, Judith, Sponseller, Craig A, Melbourne, Kathleen, Avihingsanon, Anchalee, Bustorff, Flavio, Estrada, Vicente, Ruxrungtham, Kiat, Saumoy, Maria, Navar, Ann Marie, Hoffmann, Udo, and Ribaudo, Heather J
- Subjects
CARDIOVASCULAR disease prevention ,CARDIOVASCULAR diseases risk factors ,HIV-positive persons ,DESCRIPTIVE statistics ,HEALTH behavior ,CORONARY artery disease ,BEHAVIOR modification ,DISEASE risk factors - Abstract
Background In addition to traditional cardiovascular (CV) risk factors, antiretroviral therapy, lifestyle, and human immunodeficiency virus (HIV)-related factors may contribute to future CV events in persons with HIV (PWH). Methods Among participants in the global REPRIEVE randomized trial, we characterized demographics and HIV characteristics relative to ACC/AHA pooled cohort equations (PCE) for atherosclerotic CV disease predicted risk and CV health evaluated by Life's Simple 7 (LS7; includes smoking, diet, physical activity, body mass index, blood pressure, total cholesterol, and glucose). Results Among 7382 REPRIEVE participants (31% women, 45% Black), the median PCE risk score was 4.5% (lower and upper quartiles Q1, Q3: 2.2, 7.2); 29% had a PCE score <2.5%, and 9% scored above 10%. PCE score was related closely to known CV risk factors and modestly (<1% difference in risk score) to immune function and HIV parameters. The median LS7 score was 9 (Q1, Q3: 7, 10) of a possible 14. Only 24 participants (0.3%) had 7/7 ideal components, and 36% had ≤2 ideal components; 90% had <5 ideal components. The distribution of LS7 did not vary by age or natal sex, although ideal health was more common in low sociodemographic index countries and among Asians. Poor dietary and physical activity patterns on LS7 were seen across all PCE scores, including the lowest risk categories. Conclusions Poor CV health by LS7 was common among REPRIEVE participants, regardless of PCE. This suggests a critical and independent role for lifestyle interventions in conjunction with conventional treatment to improve CV outcomes in PWH. Clinical Trials Registration: NCT02344290. AIDS Clinical Trials Group study number: A5332. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
15. Methotrexate Decreases Tenofovir Exposure in Antiretroviral-Suppressed Individuals Living With HIV.
- Author
-
Gingrich, David, Deitchman, Amelia N., Kantor, Amy, Liusheng Huang, Stein, James H., Currier, Judith S., Hsue, Priscilla Y., Ribaudo, Heather J., and Aweeka, Francesca T.
- Published
- 2020
- Full Text
- View/download PDF
16. Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial.
- Author
-
Fichtenbaum, Carl J, Ribaudo, Heather J, Leon-Cruz, Jorge, Overton, Edgar T, Zanni, Markella V, Malvestutto, Carlos D, Aberg, Judith A, Kileel, Emma M, Fitch, Kathleen V, Schalkwyk, Marije Van, Kumarasamy, Nagalingeswaran, Martinez, Esteban, Santos, Breno Riegel, Joseph, Yvetot, Lo, Janet, Siminski, Sue, Melbourne, Kathleen, Sponseller, Craig A, Desvigne-Nickens, Patrice, and Bloomfield, Gerald S
- Subjects
ANTIRETROVIRAL agents ,CD4 lymphocyte count ,CLINICAL trial registries ,BODY mass index ,LOGISTIC regression analysis - Abstract
Background: Patterns of antiretroviral therapy (ART) use and immunologic correlates vary globally, and contemporary trends are not well described.Methods: The REPRIEVE trial (Randomized Trial to Prevent Vascular Events in HIV) enrolled persons with human immunodeficiency virus (HIV) who were aged 40-75 years, receiving ART, and had low-to-moderate cardiovascular disease risk. ART use was summarized within Global Burden of Disease (GBD) super-regions, with adjusted linear and logistic regression analyses examining associations with immune parameters and key demographics.Results: A total of 7770 participants were enrolled, with a median age of 50 years (interquartile range, 45-55 years); 31% were female, 43% were black or African American, 15% were Asian, 56% had a body mass index >25 (calculated as weight in kilograms divided by height in meters squared), and 49% were current or former smokers. The median CD4 T-cell count was 620/µL (interquartile range, 447-826/ µ L), and the median duration of prior ART use, 9.5 years (5.3-14.8) years. The most common ART regimens were nucleoside/nucleotide reverse-transcriptase inhibitor (NRTI) plus nonnucleoside reverse-transcriptase inhibitor (43%), NRTI plus integrase strand transfer inhibitor (25%), and NRTI plus protease inhibitor (19%). Entry ART varied by GBD region, with shifts during the trial enrollment period. In adjusted analyses, entry CD4 cell count and CD4/CD8 ratio were associated with GBD region, sex, entry regimen, duration of ART, and nadir CD4 cell count; CD4 and CD8 cell counts were also associated with body mass index and smoking status.Conclusions: There were substantial variations in ART use by geographic region and over time, likely reflecting the local availability of specific medications, changes in treatment guidelines and provider/patient preferences. The analyses of CD4 cell counts and CD4/CD8 ratios may provide valuable insights regarding immune correlates and outcomes in people living with HIV.Clinical Trials Registration: NCT02344290. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
17. Physical Function Impairment and Frailty in Middle-Aged People Living With Human Immunodeficiency Virus in the REPRIEVE Trial Ancillary Study PREPARE.
- Author
-
Umbleja, Triin, Brown, Todd T, Overton, Edgar T, Ribaudo, Heather J, Schrack, Jennifer A, Fitch, Kathleen V, Douglas, Pamela S, Grinspoon, Steven K, Henn, Sarah, Arduino, Roberto C, Rodriguez, Benigno, Benson, Constance A, and Erlandson, Kristine M
- Subjects
MIDDLE-aged persons ,HIV ,CLINICAL trial registries ,BODY mass index ,DISABILITIES - Abstract
Background: People with human immunodeficiency virus (PWH) are at risk for accelerated development of physical function impairment and frailty; both associated with increased risk of falls, hospitalizations, and death. Identifying factors associated with physical function impairment and frailty can help target interventions.Methods: The REPRIEVE trial enrolled participants 40-75 years of age, receiving stable antiretroviral therapy with CD4+ T-cell count >100 cells/mm3, and with low to moderate cardiovascular disease risk. We conducted a cross-sectional analysis of those concurrently enrolled in the ancillary study PREPARE at enrollment.Results: Among the 266 participants, the median age was 51 years; 81% were male, and 45% were black, and 28% had hypertension. Body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) was 25 to <30 in 38% and ≥30 in 30%, 33% had a high waist circumference, 89% were physically inactive, 37% (95% confidence interval, 31%, 43%) had physical function impairment (Short Physical Performance Battery score ≤10), and 6% (4%, 9%) were frail and 42% prefrail. In the adjusted analyses, older age, black race, greater BMI, and physical inactivity were associated with physical function impairment; depression and hypertension were associated with frailty or prefrailty.Conclusions: Physical function impairment was common among middle-aged PWH; greater BMI and physical inactivity are important modifiable factors that may prevent further decline in physical function with aging.Clinical Trials Registration: NCT02344290. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
18. Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum.
- Author
-
Smeaton, Laura M, Kileel, Emma M, Grinsztejn, Beatriz, Gardner, Edward M, Starr, Kate, Murry, Melissa L, Desvigne-Nickens, Patrice, Alston-Smith, Beverly, Waclawiw, Myron A, Cooper-Arnold, Katharine, Madruga, José V, Sangle, Shashi, Fitch, Kathleen V, Zanni, Markella V, Douglas, Pamela S, Ribaudo, Heather J, Grinspoon, Steven K, and Klingman, Karin L
- Subjects
POPULATION ,GENDER identity ,WAIST circumference ,HIV ,MEDICAL care - Abstract
Because persons who identify across the transgender spectrum (PATS) are a key population in human immunodeficiency virus (HIV) yet are underreported in HIV and cardiovascular research, we aimed to characterize this population within the REPRIEVE global clinical trial (n = 7770). Acceptance of gathering gender identity was high (96%). Participation by PATS was 1.7% overall, 2.4% among natal males, 0.3% among natal females, and varied across geographic regions (from 0% in sub-Saharan Africa to 2.3% in High Income Region). Thirty percent of natal male PATS identified other than transgender. Some characteristics differed by gender. Most notably, 38% of natal male PATS receiving gender-affirming treatment had waist circumference >102 cm (compared with ≤25% in other groups). Given that PATS is a key population, HIV research should routinely report trial participation and outcomes by gender in addition to natal sex, to provide the results needed to optimize medical care to PATS. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
19. Leveraging a Landmark Trial of Primary Cardiovascular Disease Prevention in Human Immunodeficiency Virus: Introduction From the REPRIEVE Coprincipal Investigators.
- Author
-
Grinspoon, Steven K, Douglas, Pamela S, Hoffmann, Udo, and Ribaudo, Heather J
- Subjects
CARDIOVASCULAR diseases ,HIV ,PREVENTIVE medicine ,COMORBIDITY ,ANTIRETROVIRAL agents - Abstract
The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) is the largest study of cardiovascular disease in human immunodeficiency virus. Enrolling 7770 participants from 2015 to 2019 with sites across 5 continents, REPRIEVE will assess the effects of a statin as a cardiovascular disease prevention strategy in people with HIV (PWH) receiving antiretroviral therapy (ART). Although the primary purpose of REPRIEVE, and its substudy assessing coronary plaque, is to assess cardiovascular outcomes, the trial is a rich source of data on population characteristics and critical comorbidities in PWH, particularly across Global Burden of Disease (GBD) regions, reflective of the ethnic, racial, and gender diversity in this global epidemic. The purpose of this Supplement is to leverage the rich phenotyping in REPRIEVE, to provide data on detailed patterns of baseline ART and immune function by GBD region, reproductive aging among cisgender women, and data on the participation and clinical characteristics of transgender participants. We also leveraged REPRIEVE to assess critical comorbidities, including renal dysfunction, muscle function and frailty, and myocardial steatosis. REPRIEVE is a remarkable collaboration between funders, trial networks, clinical research sites, clinical and data coordinating centers, and willing participants who devoted their time to make the trial possible. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
20. Successful recruitment of a multi-site international randomized placebo-controlled trial in people with HIV with attention to diversity of race and ethnicity: critical role of central coordination.
- Author
-
Fitch, Kathleen V., Kileel, Emma M., Looby, Sara E., Zanni, Markella V., Sanchez, Laura R., Fichtenbaum, Carl J., Overton, Edgar T., Malvestutto, Carlos, Aberg, Judith A., Klingman, Karin L., Alston-Smith, Beverly, Lavelle, Judith, Rancourt, Anne, Badal-Faesen, Sharlaa, Cardoso, Sandra Wagner, Avihingsanon, Anchalee, Patil, Sandesh, Sponseller, Craig A., Melbourne, Kathleen, and Ribaudo, Heather J.
- Subjects
ETHNICITY ,MINORITY women ,AFRICAN Americans ,MINORITIES - Abstract
Background: The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) is a multicenter, randomized, placebo-controlled trial, designed to test whether a statin medication can prevent cardiovascular disease in people with HIV. REPRIEVE recently completed enrollment of 7557 participants at over 100 clinical sites globally. Participant groups of focus were women, and racial and ethnic minorities. Objective: To describe recruitment methods and strategies developed by the REPRIEVE Clinical Coordinating Center (CCC) and share best practices learned from the recruitment process. Methods: Enrollment targets were agreed upon with the primary funder, the National Heart, Lung, and Blood Institute (NHLBI) and were milestone driven. Milestones included number of sites activated, number of participants enrolled within specific time frames, and proportion of women and minorities enrolled. Strategies to achieve these milestones included structured interviews with site-designated REPRIEVE Recruitment Champions to develop best practices, development of a multimedia campaign, and site level recruitment support. Results: Recruitment initiated March, 2015 and completed March, 2019. The final accrual target was 7500 participants over 48 months. The trial met this target within the time specified. Overall, 10,613 screens were completed, 48% of participants enrolled from sites outside of North America, 32% were female, 44% were Black or African American, and 25% were Hispanic or Latino. Conclusions: REPRIEVE met its overall projected recruitment goal by using multiple, simultaneous strategies to specifically target a diverse population including minority subgroups. REPRIEVE benefited from the development of recruitment strategies with clear targets and communication of accrual targets to study teams. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
21. A Randomized, Double-blinded, Placebo-controlled Trial of Sitagliptin for Reducing Inflammation and Immune Activation in Treated and Suppressed Human Immunodeficiency Virus Infection.
- Author
-
Dubé, Michael P, Chan, Ellen S, Lake, Jordan E, Williams, Brett, Kinslow, Jennifer, Landay, Alan, Coombs, Robert W, Floris-Moore, Michelle, Ribaudo, Heather J, and Yarasheski, Kevin E
- Subjects
INFLAMMATION prevention ,ANTIGENS ,BIOMARKERS ,BLACK people ,DRUG tolerance ,HISPANIC Americans ,HIV infections ,HIV-positive persons ,IMMUNE system ,INFLAMMATORY mediators ,MEDICAL protocols ,MONOCYTES ,WHITE people ,CD4 antigen ,VIRAL load ,ANTIRETROVIRAL agents ,RANDOMIZED controlled trials ,BLIND experiment ,CD4 lymphocyte count ,PHARMACODYNAMICS ,SITAGLIPTIN ,THERAPEUTICS - Abstract
Background Dipeptidyl peptidase-4 (DPP-4) inhibitors have pleotropic anti-inflammatory and immune regulatory effects in addition to glucoregulation. We evaluated inflammation and immune markers in suppressed human immunodeficiency virus (HIV) infection during treatment with the DPP-4 inhibitor sitagliptin. Methods Virologically suppressed adults with HIV without diabetes on stable antiretroviral therapy (ART) with ≥100/μL CD4 cells were randomized to 16 weeks of sitagliptin 100 mg/day vs placebo in a multicenter trial. The primary endpoint was the change in plasma soluble CD14 (sCD14) from baseline to week 15–16. Results Ninety participants were randomized, and 42 from each arm were included in per-protocol analyses. Participants were 45% non-Hispanic white, 38% non-Hispanic black, and 15% Hispanic, with a median age of 51 years; 83% were male; and the median CD4 count was 602 cells/μL. At week 15–16, there was no difference in sCD14 change between the 2 arms (P =.69). Relative to placebo, the sitagliptin arm had 47% greater decline in CXCL10 (95% confidence interval, –57% to –35%) at week 15 (P <.001). There were no significant between-arm differences in other soluble biomarkers, total CD4 and CD8 counts, or markers of lymphocyte or monocyte activation. Sitagliptin was well tolerated. Conclusions Sixteen weeks of sitagliptin had no effect on sCD14 levels in virologically suppressed participants with HIV. CXCL10, a chemokine involved in atherogenesis that predicts non-AIDS events during ART, declined markedly with sitagliptin. This suggests that DPP-4 inhibition has the potential to reduce cardiovascular morbidity in treated HIV infection. Clinical Trials Registration NCT01426438. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
22. CHANGES IN BODY MASS INDEX WITH INTEGRASE INHIBITOR USE IN REPRIEVE.
- Author
-
Kileel, Emma, Malvestutto, Carlos, Lo, Janet, Fitch, Kathleen V., Fichtenbaum, Carl J., Aberg, Judith A., Zanni, Markella V., Martinez, Esteban, Okeke, Nwora Lance, Kumar, Princy, Joao, Esau, McCallum, Sara, Douglas, Pam S., Ribaudo, Heather J., and Grinspoon, Steven K.
- Published
- 2023
23. Safety and Impact of Low-dose Methotrexate on Endothelial Function and Inflammation in Individuals With Treated Human Immunodeficiency Virus: AIDS Clinical Trials Group Study A5314.
- Author
-
Hsue, Priscilla Y, Ribaudo, Heather J, Deeks, Steven G, Bell, Tanvir, Ridker, Paul M, Fichtenbaum, Carl, Daar, Eric S, Havlir, Diane, Yeh, Eunice, Tawakol, Ahmed, Lederman, Michael, Currier, Judith S, and Stein, James H
- Subjects
ATHEROSCLEROSIS risk factors ,HIV infection complications ,AIDS ,ATHEROSCLEROSIS ,BIOMARKERS ,CONFIDENCE intervals ,ENDOTHELIUM ,FOLIC acid ,HIV infections ,INFLAMMATION ,MEDICAL cooperation ,RESEARCH ,METHOTREXATE ,T cells ,CD4 antigen ,BRACHIAL artery ,RANDOMIZED controlled trials ,TREATMENT effectiveness ,BLIND experiment - Abstract
Background Chronic inflammation in treated HIV infection is associated with mortality and atherosclerotic cardiovascular disease (ASCVD). We evaluated the safety and potential efficacy of low-dose methotrexate (LDMTX) in treated HIV. Methods This was a phase 2 randomized, double-blind, multicenter trial in adults ≥40 years old with treated HIV, with CD4+ T-cell count ≥400 cells/μL and with/at increased risk for ASCVD. Participants received LDMTX (5–15 mg/week) or placebo (plus folic acid) for 24 weeks and were followed for an additional 12 weeks. Primary endpoints were safety and brachial artery flow-mediated dilation (FMD). Results The 176 participants (90% male) had a median (Q1, Q3) age of 54 (49, 59) years. LDMTX was associated with decreases in CD4+ T cells at week 24 and CD8+ T cells at weeks 8, 12, and 24. Eleven participants (12.8%) experienced safety events in the LDMTX group vs 5 (5.6%) in placebo (Δ = 7.2%, upper 1-sided 90% CI, 13.4%; Pnoninferiority =.037). Week 24 change in FMD was 0.47% with LDMTX and 0.09% with placebo (P =.55). No inflammatory markers changed differentially with LDMTX compared to placebo. Conclusions Adults with HIV and increased ASCVD risk treated with LDMTX had more safety events than with placebo, but the prespecified noninferiority margin of 15% was not exceeded. LDMTX had no significant effect on endothelial function or inflammatory biomarkers but was associated with a significant decrease in CD8+ T cells. The balance of risks and potential benefits of LDMTX in this population will require additional investigation. Clinical Trials Registration NCT01949116. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
24. The Use of the Restricted Mean Survival Time as a Treatment Measure in HIV/AIDS Clinical Trial: Reanalysis of the ACTG A5257 Trial.
- Author
-
Abulizi, Xianmixikemaier MPH, Ribaudo, Heather J. PhD, and Flandre, Philippe PhD
- Published
- 2019
- Full Text
- View/download PDF
25. Antiretroviral Concentrations in Hair Strongly Predict Virologic Response in a Large Human Immunodeficiency Virus Treatment-naive Clinical Trial.
- Author
-
Gandhi, Monica, Horng, Howard, Phung, Nhi, Kuncze, Karen, Bacchetti, Peter, Jin, Chengshi, Ofokotun, Igho, Sheth, Anandi N, Lennox, Jeffrey, Ribaudo, Heather J, Haas, David W, Okochi, Hideaki, Landovitz, Raphael J, and Currier, Judith S
- Subjects
ANTIRETROVIRAL agents ,HIV infections ,LONGITUDINAL method ,MEDICAL protocols ,RANDOMIZED controlled trials ,TREATMENT effectiveness ,HAIR analysis - Abstract
Concentrations of antiretrovirals in hair are associated with virologic outcomes in cohorts of human immunodeficiency virus (HIV)-positive individuals but have never been examined in a clinical trial. We show for the first time the predictive utility of hair antiretroviral concentrations in a large HIV treatment-naive trial (AIDS Clinical Trials Group protocol A5257). [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
26. Racial differences in calculated bioavailable vitamin D with vitamin D/calcium supplementation.
- Author
-
Yin, Michael T., Chan, Ellen S., Brown, Todd T., Tebas, Pablo, McComsey, Grace A., Melbourne, Kathleen M., Napoli, Andrew, Hardin, William R., Ribaudo, Heather J., Overton, Edgar T., and A5280 Study Team
- Published
- 2017
- Full Text
- View/download PDF
27. IMPACT OF COVID-19 AND HOST FACTORS ON THE HUMORAL IMMUNE REPERTOIRE IN TREATED HIV.
- Author
-
Schnittman, Samuel R., Wonyeong Jung, Fitch, Kathleen V., Zanni, Markella V., McCallum, Sara, Lee, Jessica, Shin, Sally, Davis, Brandon J., Fulda, Evelynne S., Diggs, Marissa, Currier, Judith S., Douglas, Pam S., Ribaudo, Heather J., Alter, Galit, and Grinspoon, Steven K.
- Published
- 2023
28. BASELINE AND TEMPORAL DIFFERENCES IN PROTEOMICS FOLLOWING SARS-CoV-2 INFECTION IN PWH.
- Author
-
Kolossváry, Márton, Defilippi, Christopher, McCallum, Sara, Fitch, Kathleen V., Ribaudo, Heather J., Fichtenbaum, Carl J., Aberg, Judith A., Malvestutto, Carlos, Currier, Judith S., Casado, Jose L., Gutiérrez, Félix, Sereti, Irini, Douglas, Pam S., Zanni, Markella V., and Grinspoon, Steven K.
- Published
- 2023
29. Changes in Markers of T-Cell Senescence and Exhaustion With Atazanavir-, Raltegravir-, and Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.
- Author
-
Kelesidis, Theodoros, Moser, Carlee, Stein, James H., Brown, Todd T., Tran, Thuy Tien T., Ribaudo, Heather J., Dube, Michael P., Yang, Otto O., Currier, Judith S., and McComsey, Grace A.
- Subjects
T cells ,CELLULAR aging ,ANTIVIRAL agents ,HIV ,PATHOGENIC microorganisms ,ANTIGEN analysis ,ANTI-HIV agents ,HIV infections ,IMMUNOPHENOTYPING ,LONGITUDINAL method ,RANDOMIZED controlled trials - Abstract
It is unclear whether differential roles of CD4(+) versus CD8(+) T-cell senescence/exhaustion and effects of antiretroviral therapy (ART) on these processes may contribute to morbidity in treated human immunodeficiency virus type 1 (HIV) infection. In a prospective 96-week trial, 328 HIV-infected ART-naive participants were randomly assigned to receive tenofovir-emtricitabine plus either atazanavir/ritonavir, darunavir/ritonavir, or raltegravir. Markers of CD4(+) T-cell senescence (ie, the percentage of CD28(-)CD57(+) cells among CD4(+) T cells ) and CD4(+)/CD8(+) T-cell exhaustion (ie, the percentage of PD-1(+) cells among CD4(+)/CD8(+) T cells) decreased after ART. There were no changes in markers of CD8(+) T-cell senescence after ART and no differential changes in all markers in ART groups. Senescent CD4(+) and CD8(+) T cells may have differential roles in HIV pathogenesis. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
30. Differential CD4+ cell count increase and CD4+ : CD8+ ratio normalization with maraviroc compared with tenofovir.
- Author
-
Chan, Ellen S., Landay, Alan L., Brown, Todd T., Ribaudo, Heather J., Mirmonsef, Paria, Ofotokun, Igho, Weitzmann, M. Neale, Martinson, Jeffrey, Klingman, Karin L., Eron, Joseph J., Fichtenbaum, Carl J., Plants, Jill, and Taiwo, Babafemi O.
- Published
- 2016
- Full Text
- View/download PDF
31. Comparison of the Metabolic Effects of Ritonavir-Boosted Darunavir or Atazanavir Versus Raltegravir, and the Impact of Ritonavir Plasma Exposure: ACTG 5257.
- Author
-
Ofotokun, Ighovwerha, Na, Lumine H., Landovitz, Raphael J., Ribaudo, Heather J., McComsey, Grace A., Godfrey, Catherine, Aweeka, Francesca, Cohn, Susan E., Sagar, Manish, Kuritzkes, Daniel R., Brown, Todd T., Patterson, Kristine B., Para, Michael F., Leavitt, Randi Y., Villasis-Keever, Angelina, Baugh, Bryan P., Lennox, Jeffrey L., and Currier, Judith S.
- Subjects
DARUNAVIR ,ATAZANAVIR ,RALTEGRAVIR ,HIV protease inhibitors ,PLASMA diagnostics ,THERAPEUTICS - Abstract
Background. Metabolic effects following combination antiretroviral therapy (cART) vary by regimen type. Changes in metabolic effects were assessed following cART in the AIDS Clinical Trials Group (ACTG) A5257 study, and correlated with plasma ritonavir trough concentrations (C
24 ). Methods. Treatment-naive adult subjects were randomized to ritonavir-boosted atazanavir or darunavir, or raltegravir-based cART. Changes in lipids and other metabolic outcomes over time were estimated. Differences between arms were estimated with 97.5% confidence intervals and compared using pairwise Student t tests. Associations between ritonavir C24 and lipid changes at week 48 were evaluated via linear regression. Results. Analyses included 1797 subjects with baseline fasting data. Baseline lipid profiles and metabolic syndrome rates (approximately 21%) were similar across arms. Comparable increases occurred in total cholesterol, triglycerides, and low-density lipoprotein cholesterol with the boosted protease inhibitors (PIs); each PI had greater increases relative to raltegravir (all P ≤ .001 at week 96). Metabolic syndrome incident rates by week 96 (approximately 22%) were not different across arms. Ritonavir C24 was not different by arm (P = .89) (median, 69 ng/mL and 74 ng/mL in the atazanavir and darunavir arms, respectively) and were not associated with changes in lipid measures (all P > .1). Conclusions. Raltegravir produced the most favorable lipid profile. Metabolic syndrome rates were high at baseline and increased to the same degree in all arms. Ritonavir C24 was not different in the PI arms and had no relationship with the modest but comparable increases in lipids observed with either atazanavir or darunavir. The long-term clinical significance of the lipid changes noted with the PIs relative to raltegravir deserves further evaluation. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
32. Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s.
- Author
-
McComsey, Grace A., Moser, Carlee, Currier, Judith, Ribaudo, Heather J., Paczuski, Pawel, Dubé, Michael P., Kelesidis, Theodoros, Rothenberg, Jennifer, Stein, James H., and Brown, Todd T.
- Subjects
BODY composition ,RALTEGRAVIR ,PROTEASE inhibitors ,HIGHLY active antiretroviral therapy ,COMPUTED tomography ,THERAPEUTICS - Abstract
Background. Fat gain after antiretroviral therapy (ART) occurs, and its association with protease inhibitors (PIs) is unclear. Methods. Peripheral and central fat depots and lean mass were measured using standardized and centrally read abdominal CT scans and whole-body dual-energy absorptiometry scans over a 96-week period in human immunodeficiency virus (HIV)-infected treatment-naive participants. The patients were randomized to tenofovir-emtricitabine (TDF/FTC) plus atazanavir-ritonavir (ATV/ r), darunavir-ritonavir (DRV/r), or raltegravir (RAL) in ACTG A5260s, a substudy of A5257.Within arm changes were assessed with signed-rank tests. The 96-week percentage changes in fat and lean mass in the 2 PI arms were not different, thus the PI arms were combined and compared to the RAL arm. Associations between baseline biomarkers and changes in body composition were assessed. All analyses used linear regression models. Results. 328 patients were randomized (90% male, 44% white non-Hispanic). The median age was 36 years, HIV-1 RNA 4.6 log10 copies/mL, and CD4 349 cells/μL. Overall, at week 96, increases in limb fat (13.4%), subcutaneous (19.9%) and visceral abdominal fat (25.8%), trunk fat (18%), and lean mass (1.8%) were apparent (P < .001 for changes within each arm). Changes for all fat and lean outcomes were not different between the PI arms or between the RAL and the combined PI arms. Higher baseline HIV-1 RNA levels were associated with greater gains in peripheral and central fat. Conclusions. In treatment-naive participants initiating ART with TDF/FTC, no differences in lean mass and regional fat were found with RAL when compared with ATV/r or DRV/r over 96 weeks. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
33. Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.
- Author
-
Brown, Todd T., Moser, Carlee, Currier, Judith S., Ribaudo, Heather J., Rothenberg, Jennifer, Kelesidis, Theodoros, Otto Yang, Dubé, Michael P., Murphy, Robert L., Stein, James H., McComsey, Grace A., and Yang, Otto
- Subjects
BONE density ,ANTIRETROVIRAL agents ,TENOFOVIR ,BISOPROLOL ,EMTRICITABINE ,ATAZANAVIR ,RITONAVIR ,PROTEASE inhibitors ,COMBINATION drug therapy ,HIV ,HIV infections ,RESEARCH methodology ,RESEARCH funding ,STATISTICAL sampling ,VIRAL load ,RANDOMIZED controlled trials ,ANTI-HIV agents ,HIV integrase inhibitors ,HIV protease inhibitors ,REVERSE transcriptase inhibitors ,THERAPEUTICS - Abstract
Background: Specific antiretroviral therapy (ART) medications and the severity of human immunodeficiency virus (HIV) disease before treatment contribute to bone mineral density (BMD) loss after ART initiation.Methods: We compared the percentage change in BMD over 96 weeks in 328 HIV-infected, treatment-naive individuals randomized equally to tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) plus atazanavir/ritonavir (ATV/r), darunavir/ritonavir (DRV/r), or raltegravir (RAL). We also determined whether baseline levels of inflammation markers and immune activation were independently associated with BMD loss.Results: At week 96, the mean percentage changes from baseline in spine and hip BMDs were similar in the protease inhibitor (PI) arms (spine: -4.0% in the ATV/r group vs -3.6% in the DRV/r [P = .42]; hip: -3.9% in the ATV/r group vs -3.4% in the DRV/r group [P = .36]) but were greater in the combined PI arms than in the RAL arm (spine: -3.8% vs -1.8% [P < .001]; hip: -3.7% vs -2.4% [P = .005]). In multivariable analyses, higher baseline concentrations of high-sensitivity C-reactive protein, interleukin 6, and soluble CD14 were associated with greater total hip BMD loss, whereas markers of CD4(+) T-cell senescence and exhaustion (CD4(+)CD28(-)CD57(+)PD1(+)) and CD4(+) T-cell activation (CD4(+)CD38(+)HLA-DR(+)) were associated with lumbar spine BMD loss.Conclusions: BMD losses 96 weeks after ART initiation were similar in magnitude among patients receiving PIs, ATV/r, or DRV/r but lowest among those receiving RAL. Inflammation and immune activation/senescence before ART initiation independently predicted subsequent BMD loss. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
34. A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness.
- Author
-
Stein, James H., Ribaudo, Heather J., Hodis, Howard N., Brown, Todd T., Tran, Thuy Tien T., Mingzhu Yan, Brodell, Elizabeth Lauer, Kelesidis, Theodore, McComsey, Grace A., Dube, Michael P., Murphy, Robert L., Currier, Judith S., and Yan, Mingzhu
- Published
- 2015
- Full Text
- View/download PDF
35. Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.
- Author
-
Kelesidis, Theodoros, Tran, Thuy Tien T., Stein, James H., Brown, Todd T., Moser, Carlee, Ribaudo, Heather J., Dube, Michael P., Murphy, Robert, Yang, Otto O., Currier, Judith S., and McComsey, Grace A.
- Subjects
INFLAMMATION treatment ,IMMUNOREGULATION ,ATAZANAVIR ,RALTEGRAVIR ,DARUNAVIR ,ANTIVIRAL agents ,INTERLEUKIN-6 ,THERAPEUTICS - Abstract
Background. It is unclear whether the integrase inhibitor raltegravir (RAL) reduces inflammation and immune activation compared with ritonavir-boosted protease inhibitors (PIs). Methods. In a prospective, randomized, multicenter clinical trial that included 328 human immunodeficiency type 1 (HIV-1)-infected, treatment-naive participants were randomized to receive tenofovir disoproxil fumarateemtricitabine (TDF/FTC) plus atazanavir/ritonavir (ATV/r), darunavir/ritonavir (DRV/r), or RAL. A total of 234 participants (71%) with HIV-1 RNA levels <50 copies/mL by week 24 were included. Plasma biomarkers of inflammation and coagulation that were analysed included high-sensitivity C-reactive protein, interleukin-6 (IL-6), GlycA, D-dimer, soluble CD14 (sCD14), sCD163, and sIL-2r; blood cellular markers included %CD38+DR+ of T-cell subsets and %CD14+CD16+ and%CD14(dim)CD16+ monocyte subsets. Changes from baseline were examined at earlier (24 or 48 weeks) and later (96 weeks) time points, with 95% confidence intervals on fold-change. Pairwise treatment groups were compared using Wilcoxon rank sum tests, with P values adjusted for false discovery rate control. Results. Changes in biomarkers varied by regimen during the 96 weeks of follow-up as follows: hsCRP declined with ATV/r and RAL, IL-6 declined only with RAL, and GLycA decreased in all groups. D-dimer declined with ATV/r and DRV/r and was unchanged with RAL. Markers of T-cell activation and sCD163 (but not sCD14 and CD14-+CD16+) declined in all groups. Conclusions. Despite some differences in specific markers of inflammation and immune activation between the antiretroviral therapy (ART) regimens, we found no consistent evidence that the reduction of inflammation and immune activation with ART initiation was different between RAL and PI-based regimens. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
36. Screening for UGT1A1 Genotype in Study A5257 Would Have Markedly Reduced Premature Discontinuation of Atazanavir for Hyperbilirubinemia.
- Author
-
Vardhanabhuti, Saran, Ribaudo, Heather J., Landovitz, Raphael J., Ofotokun, Ighovwerha, Lennox, Jeffrey L., Currier, Judith S., Olson, Lana M., and Haas, David W.
- Subjects
HYPERBILIRUBINEMIA ,ATAZANAVIR ,PHARMACOGENOMICS - Abstract
Background. Some patients are not prescribed atazanavir because of concern about possible jaundice. Atazanavir- associated hyperbilirubinemia correlates with UGT1A1 rs887829 genotype. We examined bilirubin-related discontinuation of atazanavir in participants from AIDS Clinical Trials Group Study A5257. Methods. Discriminatory properties of UGT1A1 T/T genotype for predicting bilirubin-related atazanavir discontinuation through 96 weeks after antiretroviral initiation were estimated. Results. Genetic analyses involved 1450 participants, including 481 who initiated randomized atazanavir/ritonavir. Positive predictive values of rs887829 T/T for bilirubin-related discontinuation of atazanavir (with 95% confidence intervals [CIs]) were 20% (CI, 9%-36%) in Black, 60% (CI, 32%-84%) in White, and 29% (CI, 8%-58%) in Hispanic participants; negative predictive values were 97% (CI, 93%-99%), 95% (CI, 90%-98%), and 97% (CI, 90%- 100%), respectively. Conclusions. Bilirubin-related discontinuation of atazanavir was rare in participants not homozygous for rs887829 T/T, regardless of race or ethnicity. We hypothesize that the higher rate of discontinuation among White participants homozygous for rs887829 T/T may reflect differences in physical manifestations of jaundice by race and ethnicity. Selective avoidance of atazanavir initiation among individuals with T/T genotypes would markedly reduce the likelihood of bilirubin-related discontinuation of atazanavir while allowing atazanavir to be prescribed to the majority of individuals. This genetic association will also affect atazanavir/cobicistat. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
37. Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation.
- Author
-
Turner Overton, Edgar, Chan, Ellen S., Brown, Todd T., Tebas, Pablo, McComsey, Grace A., Melbourne, Kathleen M., Napoli, Andrew, Hardin, William Royce, Ribaudo, Heather J., and Yin, Michael T.
- Subjects
ANTIRETROVIRAL agents ,BONE densitometry ,PHYSIOLOGICAL effects of calcium ,PHYSIOLOGICAL effects of vitamin D ,DIAGNOSIS of bone diseases ,TENOFOVIR ,HIV infections ,THERAPEUTICS - Abstract
Background: Antiretroviral therapy initiation for HIV-1 infection is associated with 2% to 6% loss of bone mineral density (BMD). Objective: To evaluate the effect of vitamin D
3 plus calcium supplementation on bone loss associated with antiretroviral therapy initiation. Design: 48-week prospective, randomized, double-blind, placebo-controlled study. (ClinicalTrials.gov: NCT01403051) Setting: 39 AIDS Clinical Trials Group units. Patients: Adults with antiretroviral therapy-naive HIV. Measurements: BMD by dual-energy x-ray absorptiometry, 25- hydroxyvitamin D levels, and other laboratory assessments. Results: 165 eligible patients were randomly assigned (79 received vitamin D3 plus calcium and 86 received placebo). The study groups were well-balanced at baseline: 90% were men, 33% were non-Hispanic black, and the median CD4 count was 0.341 x 109 cells/L. At 48 weeks, the percentage of decline in total hip BMD was smaller in the vitamin D3 plus calcium group than in the placebo group: Medians were —1.36% (interquartile range [IQR], -3.43% to 0.50%) and -3.22% (IQR, -5.56% to -0.88%), respectively (P = 0.004). Similar results were seen at the lumbar spine. At 48 weeks, 90% of patients achieved HIV-1 RNA levels less than 50 copies/mL. Levels of 25-hydroxyvitamin D3 increased with vitamin D3 plus calcium but not with placebo: Median change was 61.2 nmol/L (IQR, 36.4 to 94.3) versus 1.7 nmol/L (IQR, -13.2 to 10.7) (P< 0.001). Overall, 103 patients (62%) reported 1 or more adverse event, with similar distribution between groups; no cases of hypercalcemia and 1 case of nephrolithiasis were reported in the placebo group. Limitation: No international sites were included, and follow-up was only 48 weeks. Conclusion: Vitamin D3 plus calcium supplementation mitigates the BMD loss seen with initiation of efavirenz/emtricitabine/tenofovir disoproxil fumarate. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
38. Comparison of the Metabolic Effects of Ritonavir-Boosted Darunavir or Atazanavir Versus Raltegravir, and the Impact of Ritonavir Plasma Exposure: ACTG 5257.
- Author
-
Ofotokun, Ighovwerha, Na, Lumine H., Landovitz, Raphael J., Ribaudo, Heather J., McComsey, Grace A., Godfrey, Catherine, Aweeka, Francesca, Cohn, Susan E., Sagar, Manish, Kuritzkes, Daniel R., Brown, Todd T., Patterson, Kristine B., Para, Michael F., Leavitt, Randi Y., Villasis-Keever, Angelina, Baugh, Bryan P., Lennox, Jeffrey L., and Currier, Judith S.
- Subjects
HIV infections ,THERAPEUTICS ,RITONAVIR ,DARUNAVIR ,ATAZANAVIR ,RALTEGRAVIR ,METABOLIC syndrome ,BLOOD plasma ,CLINICAL drug trials - Abstract
Background: Metabolic effects following combination antiretroviral therapy (cART) vary by regimen type. Changes in metabolic effects were assessed following cART in the AIDS Clinical Trials Group (ACTG) A5257 study, and correlated with plasma ritonavir trough concentrations (C24). Methods: Treatment-naive adult subjects were randomized to ritonavir-boosted atazanavir or darunavir, or raltegravir-based cART. Changes in lipids and other metabolic outcomes over time were estimated. Differences between arms were estimated with 97.5% confidence intervals and compared using pairwise Student t tests. Associations between ritonavir C24 and lipid changes at week 48 were evaluated via linear regression. Results: Analyses included 1797 subjects with baseline fasting data. Baseline lipid profiles and metabolic syndrome rates (approximately 21%) were similar across arms. Comparable increases occurred in total cholesterol, triglycerides, and low-density lipoprotein cholesterol with the boosted protease inhibitors (PIs); each PI had greater increases relative to raltegravir (all P ≤ .001 at week 96). Metabolic syndrome incident rates by week 96 (approximately 22%) were not different across arms. Ritonavir C24 was not different by arm (P = .89) (median, 69 ng/mL and 74 ng/mL in the atazanavir and darunavir arms, respectively) and were not associated with changes in lipid measures (all P > .1). Conclusions: Raltegravir produced the most favorable lipid profile. Metabolic syndrome rates were high at baseline and increased to the same degree in all arms. Ritonavir C24 was not different in the PI arms and had no relationship with the modest but comparable increases in lipids observed with either atazanavir or darunavir. The long-term clinical significance of the lipid changes noted with the PIs relative to raltegravir deserves further evaluation. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
39. Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230.
- Author
-
Kumarasamy, Nagalingeswaran, Aga, Evgenia, Ribaudo, Heather J., Wallis, Carole L., Katzenstein, David A., Stevens, Wendy S., Norton, Michael R., Klingman, Karin L., Hosseinipour, Mina C., Crump, John A., Supparatpinyo, Khuanchai, Badal-Faesen, Sharlaa, and Bartlet, John A.
- Subjects
AIDS treatment ,LOPINAVIR-ritonavir ,RITONAVIR ,VIROLOGY ,PUBLIC health ,THERAPEUTICS - Abstract
Background. The AIDS Clinical Trials Group (ACTG) A5230 study evaluated lopinavir/ritonavir (LPV/r) monotherapy following virologic failure (VF) on first-line human immunodeficiency virus (HIV) regimens in Africa and Asia. Methods. Eligible subjects had received first-line regimens for at least 6 months and had plasma HIV-1 RNA levels 1000-200 000 copies/mL. All subjects received LPV/r 400/100 mg twice daily. VF was defined as failure to suppress to <400 copies/mL by week 24, or confirmed rebound to >400 copies/mL at or after week 16 following confirmed suppression. Subjects with VF added emtricitabine 200 mg/tenofovir 300 mg (FTC/TDF) once daily. The probability of continued HIV-1 RNA <400 copies/mL on LPV/r monotherapy through week 104 was estimated with a 95% confidence interval (CI); predictors of treatment success were evaluated with Cox proportional hazards models. Results. One hundred twenty-three subjects were enrolled. Four subjects died and 2 discontinued prematurely; 117 of 123 (95%) completed 104 weeks. Through week 104, 49 subjects met the primary endpoint; 47 had VF, and 2 intensified treatment without VF. Of the 47 subjects with VF, 41 (33%) intensified treatment, and 39 of 41 subsequently achieved levels <400 copies/mL. The probability of continued suppression <400 copies/mL over 104 weeks on LPV/r monotherapy was 60% (95% CI, 50%-68%); 80%-85% maintained levels <400 copies/mL with FTC/TDF intensification as needed. Ultrasensitive assays on specimens with HIV-1 RNA level <400 copies/mL at weeks 24, 48, and 104 revealed that 61%, 62%, and 65% were suppressed to <40 copies/mL, respectively. Conclusions. LPV/r monotherapy after first-line VF with FTC/TDF intensification when needed provides durable suppression of HIV-1 RNA over 104 weeks. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
40. Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols.
- Author
-
Lehmann, David S., Ribaudo, Heather J., Daar, Eric S., Gulick, Roy M., Haubrich, Richard H., Robbins, Gregory K., de Bakker, Paul I. W., Haas, David W., and McLaren, Paul J.
- Published
- 2015
- Full Text
- View/download PDF
41. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.
- Author
-
Lennox, Jeffrey L, Landovitz, Raphael J, Ribaudo, Heather J, Ofotokun, Ighovwerha, Na, Lumine H, Godfrey, Catherine, Kuritzkes, Daniel R, Sagar, Manish, Brown, Todd T, Cohn, Susan E, McComsey, Grace A, Aweeka, Francesca, Fichtenbaum, Carl J, Presti, Rachel M, Koletar, Susan L, Haas, David W, Patterson, Kristine B, Benson, Constance A, Baugh, Bryan P, and Leavitt, Randi Y
- Abstract
Background: Nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy is not suitable for all treatment-naive HIV-infected persons.Objective: To evaluate 3 nonnucleoside reverse transcriptase inhibitor-sparing initial antiretroviral regimens to show equivalence for virologic efficacy and tolerability.Design: A phase 3, open-label study randomized in a 1:1:1 ratio with follow-up for at least 96 weeks. (ClinicalTrials.gov: NCT00811954).Setting: 57 sites in the United States and Puerto Rico.Patients: Treatment-naive persons aged 18 years or older with HIV-1 RNA levels greater than 1000 copies/mL without resistance to nucleoside reverse transcriptase inhibitors or protease inhibitors.Intervention: Atazanavir, 300 mg/d, with ritonavir, 100 mg/d; raltegravir, 400 mg twice daily; or darunavir, 800 mg/d, with ritonavir, 100 mg/d, plus combination emtricitabine, 200 mg/d, and tenofovir disoproxil fumarate, 300 mg/d.Measurements: Virologic failure, defined as a confirmed HIV-1 RNA level greater than 1000 copies/mL at or after 16 weeks and before 24 weeks or greater than 200 copies/mL at or after 24 weeks, and tolerability failure, defined as discontinuation of atazanavir, raltegravir, or darunavir for toxicity. A secondary end point was a combination of virologic efficacy and tolerability.Results: Among 1809 participants, all pairwise comparisons of incidence of virologic failure over 96 weeks showed equivalence within a margin of equivalence defined as -10% to 10%. Raltegravir and ritonavir-boosted darunavir were equivalent for tolerability, whereas ritonavir-boosted atazanavir resulted in a 12.7% and 9.2% higher incidence of tolerability discontinuation than raltegravir and ritonavir-boosted darunavir, respectively, primarily because of hyperbilirubinemia. For combined virologic efficacy and tolerability, ritonavir-boosted darunavir was superior to ritonavir-boosted atazanavir, and raltegravir was superior to both protease inhibitors. Antiretroviral resistance at the time of virologic failure was rare but more frequent with raltegravir.Limitation: The trial was open-label, and ritonavir was not provided.Conclusion: Over 2 years, all 3 regimens attained high and equivalent rates of virologic control. Tolerability of regimens containing raltegravir or ritonavir-boosted darunavir was superior to that of the ritonavir-boosted atazanavir regimen.Primary Funding Source: National Institute of Allergy and Infectious Diseases. [ABSTRACT FROM AUTHOR]- Published
- 2014
- Full Text
- View/download PDF
42. Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor-Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1.
- Author
-
Lennox, Jeffrey L., Landovitz, Raphael J., Ribaudo, Heather J., Ofotokun, Ighovwerha, Na, Lumine H., Godfrey, Catherine, Kuritzkes, Daniel R., Sagar, Manish, Brown, Todd T., Cohn, Susan E., McComsey, Grace A., Aweeka, Francesca, Fichtenbaum, Carl J., Presti, Rachel M., Koletar, Susan L., Haas, David W., Patterson, Kristine B., Benson, Constance A., Baugh, Bryan P., and Leavitt, Randi Y.
- Subjects
REVERSE transcriptase inhibitors ,ANTIRETROVIRAL agents ,THERAPEUTICS ,HIV infections ,HIV-positive persons ,ATAZANAVIR ,RALTEGRAVIR - Abstract
Background: Nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy is not suitable for all treatment-naive HIV-infected persons. Objective: To evaluate 3 nonnucleoside reverse transcriptase inhibitor-sparing initial antiretroviral regimens to show equivalence for virologic efficacy and tolerability. Design: A phase 3, open-label study randomized in a 1:1:1 ratio with follow-up for at least 96 weeks. (ClinicalTrials.gov: NCT00811954) Setting: 57 sites in the United States and Puerto Rico. Patients: Treatment-naive persons aged 18 years or older with HIV-1 RNA levels greater than 1000 copies/mL without resistance to nucleoside reverse transcriptase inhibitors or protease inhibitors. Intervention: Atazanavir, 300 mg/d, with ritonavir, 100 mg/d; raltegravir, 400 mg twice daily; or darunavir, 800 mg/d, with ritonavir, 100 mg/d, plus combination emtricitabine, 200 mg/d, and tenofovir disoproxil fumarate, 300 mg/d. Measurements: Virologic failure, defined as a confirmed HIV-1 RNA level greater than 1000 copies/mL at or after 16 weeks and before 24 weeks or greater than 200 copies/mL at or after 24 weeks, and tolerability failure, defined as discontinuation of atazanavir, raltegravir, or darunavir for toxicity. A secondary end point was a combination of virologic efficacy and tolerability. Results: Among 1809 participants, all pairwise comparisons of incidence of virologic failure over 96 weeks showed equivalence within a margin of equivalence defined as -10 % to 10%. Raltegravir and ritonavir-boosted darunavir were equivalent for tolerability, whereas ritonavir-boosted atazanavir resulted in a 12.7% and 9.2% higher incidence of tolerability discontinuation than raltegravir and ritonavir-boosted darunavir, respectively, primarily because of hyperbilirubinemia. For combined virologic efficacy and tolerability, ritonavir-boosted darunavir was superior to ritonavir-boosted atazanavir, and raltegravir was superior to both protease inhibitors. Antiretroviral resistance at the time of virologic failure was rare but more frequent with raltegravir. Limitation: The trial was open-label, and ritonavir was not provided. Conclusion: Over 2 years, all 3 regimens attained high and equivalent rates of virologic control. Tolerability of regimens containing raltegravir or ritonavir-boosted darunavir was superior to that of the ritonavir-boosted atazanavir regimen. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
43. Racial Differences in Response to Antiretroviral Therapy for HIV Infection: An AIDS Clinical Trials Group (ACTG) Study Analysis.
- Author
-
Ribaudo, Heather J., Smith, Kimberly Y., Robbins, Gregory K., Flexner, Charles, Haubrich, Richard, Chen, Yun, Fischl, Margaret A., Schackman, Bruce R., Riddler, Sharon A., and Gulick, Roy M.
- Subjects
ANTIRETROVIRAL agents ,THERAPEUTICS ,HIV infections ,VIROLOGY ,CLINICAL trials ,AIDS ,SCIENTIFIC observation ,SOCIAL factors - Abstract
Blacks had a 40% higher risk of virologic failure on initial antiretroviral therapy compared to whites. This observation was consistent over a broad range of regimens, suggesting it may be driven by unmeasured social factors; biological factors cannot be ruled out.Background. In the United States, black individuals infected with human immunodeficiency virus (HIV) have higher rates of virologic failure on antiretroviral therapy (ART) and of death compared to white individuals. The cause for these disparities is uncertain. We sought to examine differences in virologic outcomes among antiretroviral-naive clinical trial participants starting randomized ART and to investigate factors to explain the differences.Methods. Individual-level data from participants initiating ART in 5 AIDS Clinical Trials Group studies were analyzed. Included studies were those conducted during 1998–2006 with a primary outcome of virologic failure. The primary outcome measure was time to virologic failure, regardless of ART changes.Results. A total of 2495 individuals (1151 black; 1344 white) were included with a median follow-up of 129 weeks. Compared to whites, blacks had an increased hazard of virologic failure (hazard ratio [HR]; 1.7; 95% confidence interval [CI], 1.4–1.9; P < .001), with no evidence of heterogeneity across regimens (P = .97); the association remained after adjustment for measured confounders (HR, 1.4; 95% CI, 1.2–1.6; P < .001). Increased hazard of virologic failure was associated with younger age, higher pretreatment HIV type 1 RNA level, lower pretreatment CD4 cell count, hepatitis C antibody, less education, and recent nonadherence to treatment. Sensitivity analyses with different endpoint definitions demonstrated similar results.Conclusions. In this analysis, blacks had a 40% higher virologic failure risk than whites that was not explained by measured confounders. The observation was consistent over a range of regimens, suggesting that the difference may be driven by social factors; however, biological factors cannot be ruled out. Further research should identify the sources of racial disparities and develop strategies to reduce them. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
44. Clinical and Genetic Determinants of Plasma Nevirapine Exposure Following an Intrapartum Dose to Prevent Mother-to-Child HIV Transmission.
- Author
-
Vardhanabhuti, Saran, Acosta, Edward P., Ribaudo, Heather J., Severe, Patrice, Lalloo, Umesh, Kumarasamy, Nagalingeshwaran, Taulo, Frank, Kabanda, Joseph, Oneko, Olola, Ive, Prudence, Sambarey, Pradeep, Chan, Ellen S., Hitti, Jane, Hong, Francis, McMahon, Deborah, and Haas, David W.
- Subjects
NEVIRAPINE ,HIV infection transmission ,HUMAN genetics ,PHARMACOKINETICS ,DRUG resistance ,GENETIC mutation - Abstract
Objective. Nevirapine is metabolized by cytochrome P450 (CYP) 2B6 and CYP3A4. We characterized relationships between clinical parameters, human genetics, pharmacokinetics, and human immunodeficiency virus type 1 (HIV-1) drug resistance mutations in pregnant women following single-dose intrapartum nevirapine.Methods. In AIDS Clinical Trials Group study A5207, women received nevirapine at onset of labor and were randomly assigned to receive lamivudine/zidovudine, emtricitabine/tenofovir, or lopinavir/ritonavir for 7 or 21 days. Plasma nevirapine level was quantified on postpartum day 1 and on weeks 1, 3, and 5. We assayed 214 polymorphisms in CYP2B6 and other genes and evaluated associations with pharmacokinetic parameters, including elimination constant, time to protein-adjusted 50% inhibitory concentration (IC50), and week 5 nevirapine level below the quantification limit.Results. Among 301 women with evaluable pharmacokinetic and genotype data, lower body mass index and random assignment to receive lopinavir/ritonavir were associated with more rapid nevirapine elimination. Among those of African ancestry, longer time to IC50 was associated with CYP2B6 983T→C (P = .004) but not with CYP2B6 516G→T (P = .8). Among Indians, slower nevirapine elimination was associated with CYP2B6 516G→T (P = .04). Emergent resistance was infrequent and not associated with pharmacokinetics or CYP2B6 genotype.Conclusions. The effects on plasma drug exposure following single-dose nevirapine may be greater for CYP2B6 983T→C than for 516G→T and are less pronounced than at steady state. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
45. Body Composition, Soluble Markers of Inflammation, and Bone Mineral Density in Antiretroviral Therapy-Naive HIV-1-Infected Individuals.
- Author
-
Brown, Todd T., Chen, Yun, Currier, Judith S., Ribaudo, Heather J., Rothenberg, Jennifer, Dubé, Michael P., Murphy, Robert, Stein, James H., and McComsey, Grace A.
- Published
- 2013
- Full Text
- View/download PDF
46. Ultrasonographic measures of cardiovascular disease risk in antiretroviral treatment-naive individuals with HIV infection.
- Author
-
Stein, James H, Brown, Todd T, Ribaudo, Heather J, Chen, Yun, Yan, Mingzhu, Lauer-Brodell, Elizabeth, McComsey, Grace A, Dubé, Michael P, Murphy, Robert L, Hodis, Howard N, and Currier, Judith S
- Published
- 2013
- Full Text
- View/download PDF
47. Impact of Minority Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations on Resistance Genotype After Virologic Failure.
- Author
-
Li, Jonathan Z., Paredes, Roger, Ribaudo, Heather J., Kozal, Michael J., Svarovskaia, Evguenia S., Johnson, Jeffrey A., Geretti, Anna Maria, Metzner, Karin J., Jakobsen, Martin R., Hullsiek, Katherine Huppler, Ostergaard, Lars, Miller, Michael D., and Kuritzkes, Daniel R.
- Subjects
NON-nucleoside reverse transcriptase inhibitors ,GENETIC mutation ,NATURAL immunity ,VIROLOGY ,HIV ,LOGISTIC regression analysis ,DRUG resistance - Abstract
Drug-resistant human immunodeficiency virus type 1 (HIV-1) minority variants increase the risk of virologic failure for first-line nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimens. We performed a pooled analysis to evaluate the relationship between NNRTI-resistant minority variants and the likelihood and types of resistance mutations detected at virologic failure. In multivariable logistic regression analysis, higher NNRTI minority variant copy numbers, non-white race, and nevirapine use were associated with a higher risk of NNRTI resistance at virologic failure. Among participants on efavirenz, K103N was the most frequently observed resistance mutation at virologic failure regardless of the baseline minority variant. However, the presence of baseline Y181C minority variant was associated with a higher probability of Y181C detection after virologic failure. NNRTI regimen choice and preexisting NNRTI-resistant minority variants were both associated with the probability and type of resistance mutations detected after virologic failure. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
48. Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure.
- Author
-
Li, Jonathan Z, Paredes, Roger, Ribaudo, Heather J, Kozal, Michael J, Svarovskaia, Evguenia S, Johnson, Jeffrey A, Geretti, Anna Maria, Metzner, Karin J, Jakobsen, Martin R, Hullsiek, Katherine Huppler, Ostergaard, Lars, Miller, Michael D, and Kuritzkes, Daniel R
- Abstract
Drug-resistant human immunodeficiency virus type 1 (HIV-1) minority variants increase the risk of virologic failure for first-line nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimens. We performed a pooled analysis to evaluate the relationship between NNRTI-resistant minority variants and the likelihood and types of resistance mutations detected at virologic failure. In multivariable logistic regression analysis, higher NNRTI minority variant copy numbers, non-white race, and nevirapine use were associated with a higher risk of NNRTI resistance at virologic failure. Among participants on efavirenz, K103N was the most frequently observed resistance mutation at virologic failure regardless of the baseline minority variant. However, the presence of baseline Y181C minority variant was associated with a higher probability of Y181C detection after virologic failure. NNRTI regimen choice and preexisting NNRTI-resistant minority variants were both associated with the probability and type of resistance mutations detected after virologic failure. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
49. Impact of UGT1A1 Gilbert Variant on Discontinuation of Ritonavir-Boosted Atazanavir in AIDS Clinical Trials Group Study A5202.
- Author
-
Ribaudo, Heather J., Daar, Eric S., Tierney, Camlin, Morse, Gene D., Mollan, Katie, Sax, Paul E., Fischl, Margaret A., Collier, Ann C., and Haas, David W.
- Subjects
HYPERBILIRUBINEMIA ,ATAZANAVIR ,HIV ,BILIRUBIN ,EMTRICITABINE ,RITONAVIR ,LAMIVUDINE - Abstract
The UGT1A1*28 variant has been associated with hyperbilirubinemia and atazanavir discontinuation. Protocol A5202 randomly assigned human immunodeficiency virus type 1 (HIV-1)–infected patients to receive atazanavir/ritonavir (atazanavir/r) or efavirenz, with tenofovir/emtricitabine or abacavir/lamivudine. A total of 646 atazanavir/r recipients were evaluable for UGT1A1. Homozygosity for *28/*28 was present in 8% of whites, 24% of blacks, and 18% of Hispanics and was associated with increased bilirubin concentrations. There was an association between *28/*28 and increased atazanavir/r discontinuation among Hispanic participants (P = .005) but not among white or black participants (P = .79 and P = .46, respectively). The positive predictive value of 28*/28* for atazanavir/r discontinuation among Hispanic participants was only 32% (95% confidence interval, 16%–52%). [ABSTRACT FROM PUBLISHER]
- Published
- 2013
- Full Text
- View/download PDF
50. Highly Active Antiretroviral Therapy and Adverse Birth Outcomes Among HIV-Infected Women in Botswana.
- Author
-
Chen, Jennifer Y., Ribaudo, Heather J., Souda, Sajini, Parekh, Natasha, Ogwu, Anthony, Lockman, Shahin, Powis, Kathleen, Dryden-Peterson, Scott, Creek, Tracy, Jimbo, William, Madidimalo, Tebogo, Makhema, Joseph, Essex, Max, and Shapiro, Roger L
- Subjects
ANTIRETROVIRAL agents ,DRUG side effects ,TREATMENT effectiveness ,THERAPEUTICS ,HIV infections ,PREGNANCY ,AIDS in women ,CHILDBIRTH - Abstract
Background. It is unknown whether adverse birth outcomes are associated with maternal highly active antiretroviral therapy (HAART) in pregnancy, particularly in resource-limited settings.Methods. We abstracted obstetrical records at 6 sites in Botswana for 24 months. Outcomes included stillbirths (SBs), preterm delivery (PTD), small for gestational age (SGA), and neonatal death (NND). Among human immunodeficiency virus (HIV)–infected women, comparisons were limited to HAART exposure status at conception, and those with similar opportunities for outcomes. Comparisons were adjusted for CD4+ lymphocyte cell count.Results. Of 33 148 women, 32 113 (97%) were tested for HIV, of whom 9504 (30%) were HIV infected. Maternal HIV was significantly associated with SB, PTD, SGA, and NND. Compared with all other HIV-infected women, those continuing HAART from before pregnancy had higher odds of PTD (adjusted odds ratio [AOR], 1.2; 95% confidence interval [CI], 1.1, 1.4), SGA (AOR, 1.8; 95% CI, 1.6, 2.1) and SB (AOR, 1.5; 95% CI, 1.2, 1.8). Among women initiating antiretroviral therapy in pregnancy, HAART use (vs zidovudine) was associated with higher odds of PTD (AOR, 1.4; 95% CI, 1.2, 1.8), SGA (AOR, 1.5; 95% CI, 1.2, 1.9), and SB (AOR, 2.5; 95% CI, 1.6, 3.9). Low CD4+ was independently associated with SB and SGA, and maternal hypertension during pregnancy with PTD, SGA, and SB.Conclusions. HAART receipt during pregnancy was associated with increased PTD, SGA, and SB. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.